The investments in prescription digital therapeutics (PDT) and digital therapeutics (DTx) continue. The most recent available data shows annual investment in digital therapeutics reached $14.7 billion in 2021 (see Prescription Digital Therapeutics: Applying Medicaid Experience To Value Assessment And Formulary Management). And, over the past four years, there have been significant investments announced.

For example, Samsung Electronics recently agreed to acquire Xealth, a U.S.-based platform that enables clinicians to prescribe and monitor digital health tools (see Samsung Electronics Acquires Xealth, Bridging The Gap Between Wellness And Medical Care). And last month, Boehringer Ingelheim and Click Therapeutics announced that their investigational prescription digital therapeutic, CT-155, used as an adjunct to antipsychotic therapy, significantly reduced negative…